[Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Zhonghua Zhong Liu Za Zhi
; 42(8): 624-628, 2020 Aug 23.
Article
en Zh
| MEDLINE
| ID: mdl-32867452
ABSTRACT
Small cell lung cancer (SCLC), a special type of lung cancer, is a highly malignant neuroendocrine tumor with strong invasiveness and rapid progression. SCLC is sensitive to radiotherapy and chemotherapy, so radiotherapy and chemotherapy have been the main first-line treatment of SCLC. However, it is easy to develop drug resistance after treatment. Therefore, the study of anti-angiogenic therapy has attracted more and more attention. At present, anti-angiogenic drugs mainly focus on four categories monoclonal antibodies (such as bevacizumab), endogenous angiogenesis inhibitors (such as endostar), anti-angiogenic fusion protein (such as aflibercept) and small molecular tyrosine kinase inhibitors (such as anlotinib). There are still some bottlenecks in the research and clinical application of antiangiogenic drugs. It is the right direction to explore better combination therapy and effective dual-field and multi-target drugs.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de la Angiogénesis
/
Carcinoma Pulmonar de Células Pequeñas
/
Neoplasias Pulmonares
/
Neovascularización Patológica
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
Zh
Año:
2020
Tipo del documento:
Article